AstraZeneca PLC (NASDAQ:AZN) Stock Holdings Boosted by Elevation Point Wealth Partners LLC

Elevation Point Wealth Partners LLC increased its stake in AstraZeneca PLC (NASDAQ:AZN) by 23.3% in the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 55,075 shares of the company’s stock after purchasing an additional 10,422 shares during the quarter. Elevation Point Wealth Partners LLC’s holdings in AstraZeneca were worth $4,048,000 at the end of the most recent quarter.

Several other institutional investors have also bought and sold shares of AZN. Banque Transatlantique SA acquired a new stake in AstraZeneca in the fourth quarter worth about $26,000. Confluence Investment Management LLC purchased a new stake in AstraZeneca during the first quarter valued at about $27,000. Mascagni Wealth Management Inc. purchased a new stake in AstraZeneca during the fourth quarter valued at about $29,000. CoreCap Advisors LLC lifted its stake in AstraZeneca by 31.8% during the fourth quarter. CoreCap Advisors LLC now owns 642 shares of the company’s stock valued at $42,000 after buying an additional 155 shares in the last quarter. Finally, Financial Management Professionals Inc. increased its holdings in shares of AstraZeneca by 34.4% in the 1st quarter. Financial Management Professionals Inc. now owns 781 shares of the company’s stock valued at $57,000 after purchasing an additional 200 shares during the period. Institutional investors and hedge funds own 20.35% of the company’s stock.

AstraZeneca Trading Down 0.8%

NASDAQ:AZN opened at $74.42 on Friday. The stock’s 50 day moving average price is $69.81 and its 200 day moving average price is $70.26. AstraZeneca PLC has a 52 week low of $61.24 and a 52 week high of $87.68. The company has a market capitalization of $230.80 billion, a P/E ratio of 32.93, a P/E/G ratio of 1.42 and a beta of 0.38. The company has a debt-to-equity ratio of 0.65, a quick ratio of 0.74 and a current ratio of 0.93.

AstraZeneca (NASDAQ:AZN) last announced its earnings results on Tuesday, April 29th. The company reported $1.24 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $1.10 by $0.14. The firm had revenue of $13.59 billion during the quarter, compared to analysts’ expectations of $13.71 billion. AstraZeneca had a return on equity of 32.23% and a net margin of 13.01%. The company’s revenue was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the business earned $2.06 earnings per share. On average, research analysts forecast that AstraZeneca PLC will post 4.51 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Separately, BNP Paribas started coverage on AstraZeneca in a report on Tuesday, April 15th. They issued an “outperform” rating and a $75.00 target price on the stock. One research analyst has rated the stock with a hold rating, five have given a buy rating and two have issued a strong buy rating to the company’s stock. Based on data from MarketBeat.com, AstraZeneca currently has a consensus rating of “Buy” and an average price target of $85.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company’s marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.